Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Semb, K. A.
Right arrow Articles by Oian, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Semb, K. A.
Right arrow Articles by Oian, P.

Journal of Clinical Oncology, Vol 16, 3426-3432, Copyright © 1998 by American Society of Clinical Oncology


ARTICLES

Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment

KA Semb, S Aamdal and P Oian
Department of Oncology, The Norwegian Radium Hospital, Oslo. kasemb@online.no

PURPOSE: The aim of our study was to elucidate whether the fluid retention syndrome induced by docetaxel is caused by capillary protein leakage or by other mechanisms. PATIENTS AND METHODS: Twenty-four patients with advanced or metastatic non-small-cell lung cancer (NSCLC; 23 patients) or metastatic head and neck cancer (one patient) were included on this prospective, nonrandomized trial. Docetaxel 100 mg/m2 was administered every 3 weeks with 5 days of dexamethasone prophylaxis to avoid hypersensitivity reactions and edema formation. Transcapillary forces, ie, colloid osmotic pressure of plasma (COPpl) and interstitial fluid (COPint) and interstitial hydrostatic pressure (Pint), were measured before the start of treatment and after total docetaxel doses of 200 and 500 mg/m2 by means of the well-documented wick and wick-in- needle methods. Body weight, degree of edema, blood pressure, and heart rate and hemoglobin, hematocrit, albumin, and total protein values were registered in parallel. RESULTS: After a total docetaxel dose of 200 mg/m2, COPpl, COPint, and hemoglobin, hematocrit, albumin, and total protein values had decreased significantly; Pint and body weight were unchanged; and only mild edema was observed. These findings suggest a plasma volume increase followed by enhanced fluid filtration to the interstitium. After a cumulative docetaxel dose of 500 mg/m2, the COPpl continued to decrease significantly, but COPint remained unchanged despite a significant increase in mean body weight and edema formation. These observations support the theory of a capillary protein leakage. CONCLUSION: Docetaxel appears to induce an initial enhancement of fluid filtration followed by a capillary protein leakage that leads to edema formation.


This article has been cited by other articles:


Home page
ChestHome page
V. Liu, D. A. White, M. F. Zakowski, W. Travis, M. G. Kris, M. S. Ginsberg, V. A. Miller, and C. G. Azzoli
Pulmonary Toxicity Associated With Erlotinib
Chest, September 1, 2007; 132(3): 1042 - 1044.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
B. A. Borge, V. V. Iversen, and R. K. Reed
Changes in plasma protein extravasation in rat skin during inflammatory challenges evaluated by microdialysis
Am J Physiol Heart Circ Physiol, May 1, 2006; 290(5): H2108 - H2115.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
I. Dimopoulou, A. Bamias, P. Lyberopoulos, and M. A. Dimopoulos
Pulmonary toxicity from novel antineoplastic agents
Ann. Onc., March 1, 2006; 17(3): 372 - 379.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Heart Circ. Physiol.Home page
A. Bronstad, A. Berg, and R. K. Reed
Effects of the taxanes paclitaxel and docetaxel on edema formation and interstitial fluid pressure
Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H963 - H968.
[Abstract] [Full Text] [PDF]


Home page
RadiologyHome page
J.-P. Delille, P. J. Slanetz, E. D. Yeh, E. F. Halpern, D. B. Kopans, and L. Garrido
Invasive Ductal Breast Carcinoma Response to Neoadjuvant Chemotherapy: Noninvasive Monitoring with Functional MR Imaging— Pilot Study
Radiology, July 1, 2003; 228(1): 63 - 69.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
E. Briasoulis and N. Pavlidis
Noncardiogenic Pulmonary Edema: An Unusual and Serious Complication of Anticancer Therapy
Oncologist, April 1, 2001; 6(2): 153 - 161.
[Abstract] [Full Text]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 1998 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online